| scholarly article | Q13442814 |
| P50 | author | Bert H O'Neil | Q89747251 |
| Robert Z Orlowski | Q91428664 | ||
| E Claire Dees | Q109984365 | ||
| P2093 | author name string | Peter M Voorhees | |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6316-6325 | |
| P577 | publication date | 2003-12-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | The proteasome as a target for cancer therapy | |
| P478 | volume | 9 |
| Q90369163 | (-)-Homosalinosporamide A and Its Mode of Proteasome Inhibition: An X-ray Crystallographic Study |
| Q47781392 | 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. |
| Q52676389 | 2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy. |
| Q37012453 | A Connexin50 Mutant, CX50fs, That Causes Cataracts Is Unstable, but Is Rescued by a Proteasomal Inhibitor |
| Q34629803 | A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias |
| Q33946183 | A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer |
| Q34307050 | A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers |
| Q83226303 | A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells |
| Q42048178 | A(1,3)-strain enabled retention of chirality during bis-cyclization of beta-ketoamides: total synthesis of (-)-salinosporamide A and (-)-homosalinosporamide A. |
| Q26849940 | Advances in the understanding of mechanisms and therapeutic use of bortezomib |
| Q41943563 | Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy |
| Q36526950 | Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. |
| Q40406392 | Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells |
| Q37313694 | Bcl6 is expressed in neuroblastoma: tumor cell type-specific expression predicts outcome |
| Q34685653 | Bioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects |
| Q41285042 | Bioinspired Total Synthesis and Human Proteasome Inhibitory Activity of (−)-Salinosporamide A, (−)-Homosalinosporamide A, and Derivatives Obtained via Organonucleophile Promoted Bis-cyclizations |
| Q36407085 | Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma |
| Q34189435 | Bortezomib in kidney transplantation |
| Q40273993 | Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8. |
| Q48737325 | Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord |
| Q33617012 | Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve. |
| Q35569092 | Breast cancer cell line MCF7 escapes from G1/S arrest induced by proteasome inhibition through a GSK-3β dependent mechanism. |
| Q35849327 | Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities |
| Q36600420 | Cancer proteomics by quantitative shotgun proteomics |
| Q37086070 | Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer |
| Q39507481 | Catechol polymers for pH-responsive, targeted drug delivery to cancer cells. |
| Q37204538 | Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells |
| Q47120603 | Characterization of a rat model of bortezomib-induced painful neuropathy. |
| Q37170634 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics |
| Q34313670 | Combination Therapy With VELCADE and Tissue Plasminogen Activator Is Neuroprotective in Aged Rats After Stroke and Targets MicroRNA-146a and the Toll-Like Receptor Signaling Pathway |
| Q37273485 | Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma |
| Q39649112 | Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis. |
| Q37681877 | Comparative proteomics analysis of oral cancer cell lines: identification of cancer associated proteins |
| Q24642621 | Concise total synthesis of (+/-)-salinosporamide A, (+/-)-cinnabaramide A, and derivatives via a bis-cyclization process: implications for a biosynthetic pathway? |
| Q34300719 | Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression |
| Q37956405 | Current Status of Targeted Therapies for Mantle Cell Lymphoma |
| Q37738476 | Current status of bortezomib in the treatment of multiple myeloma |
| Q35824491 | Differential cell adhesion of breast cancer stem cells on biomaterial substrate with nanotopographical cues |
| Q24652817 | Discovery and characterization of a marine bacterial SAM-dependent chlorinase |
| Q34606802 | Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma |
| Q37520891 | Effects of an anticarcinogenic Bowman-Birk protease inhibitor on purified 20S proteasome and MCF-7 breast cancer cells |
| Q34283058 | Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro |
| Q37255356 | Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1 |
| Q37212412 | Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins |
| Q35800503 | Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy |
| Q38172300 | Future agents and treatment directions in multiple myeloma |
| Q34534191 | HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo |
| Q30983130 | Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data |
| Q36721347 | Identification of Multiple Novel Protein Biomarkers Shed by Human Serous Ovarian Tumors into the Blood of Immunocompromised Mice and Verified in Patient Sera |
| Q37444479 | Identification of survival genes in human glioblastoma cells by small interfering RNA screening |
| Q34537960 | Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). |
| Q36217025 | Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice |
| Q37271116 | Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells |
| Q24338482 | Inhibition of macroautophagy triggers apoptosis |
| Q91975321 | Inhibition of microRNA-155 Reduces Neuropathic Pain During Chemotherapeutic Bortezomib via Engagement of Neuroinflammation |
| Q37434495 | Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression |
| Q35071551 | MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest? |
| Q29615707 | Modulation of oxidative stress as an anticancer strategy |
| Q34013972 | NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells |
| Q34985999 | NOB1 is essential for the survival of RKO colorectal cancer cells |
| Q39181880 | Network-based identification of key proteins involved in apoptosis and cell cycle regulation. |
| Q36928677 | Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis |
| Q38977283 | Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition |
| Q37687338 | Overcoming adaptive resistance in mucoepidermoid carcinoma through inhibition of the IKK-β/IκBα/NFκB axis |
| Q42632400 | Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. |
| Q38335306 | PNAS-4 expression and its relationship to p53 in colorectal cancer |
| Q33378628 | Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. |
| Q52351127 | Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer |
| Q92157489 | Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders |
| Q58796147 | Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy |
| Q38202977 | Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma |
| Q39490796 | Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response |
| Q28475914 | Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells |
| Q35874863 | Quantitative Proteomic Analysis Revealed 4-(Methylnitrosamino)-1-(3-pyridinyl)-1-butanone-Induced Up-Regulation of 20S Proteasome in Cultured Human Fibroblast Cells |
| Q35972588 | Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib |
| Q33307879 | Role of the ubiquitin proteasome system in renal cell carcinoma |
| Q35939318 | SEL1L, an UPR response protein, a potential marker of colonic cell transformation |
| Q46577984 | Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment |
| Q34226021 | Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density |
| Q33629972 | Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors |
| Q34060635 | The docking protein p130Cas regulates cell sensitivity to proteasome inhibition |
| Q37393379 | The immunoproteasome as a target in hematologic malignancies |
| Q35824929 | The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery |
| Q28484018 | Triptolide Inhibits the Proliferation of Prostate Cancer Cells and Down-Regulates SUMO-Specific Protease 1 Expression |
| Q35354212 | Ubiquitin-independent proteasomal degradation during oncogenic viral infections |
| Q42385107 | Understanding the multiple biological aspects leading to myeloma |
| Q34991321 | Update on clinical radiobiology |
| Q35905929 | Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib |
| Q42521548 | Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis |
| Q34473136 | Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity |
| Q80098830 | [Designer-drugs in tumor treatment] |
| Q43098314 | c-Cbl is not required for ERK1/2-dependent degradation of BimEL. |
Search more.